On June 7-9, 2023, NeuBase Therapeutics, Inc. (Nasdaq: NBSE) will be showcasing their Stealth Editors™ at the Jefferies Healthcare Conference at the Marriott Marquis in New York, NY. NeuBase is a biotechnology company that specializes in gene editing without triggering the body’s immune system.
Management of NeuBase will be actively participating in the conference to showcase their development in gene editing. This upcoming conference is sure to be an exciting showcase of the progress NeuBase has made and the possibilities it has for the future of gene editing.
Presentation Details for the Jefferies Healthcare Conference
Join us for NeuBase Therapeutics’ live corporate presentation on Friday, June 9th at 8:00 a.m. ET in Track 1! Don’t miss out on this unique opportunity to get a first-hand look at the company’s business operations. During the presentation, you’ll also be able to listen in on our webcast and interact with company leaders. So, get ready to discover what the future holds for NeuBase Therapeutics and make sure to attend this informative event!
Please contact your representative at Jefferies to schedule a one-on-one meeting with NeuBase management during the conference.
About NeuBase Therapeutics
NeuBase is revolutionizing the genome editing industry with Stealth Editing™, a groundbreaking technology that presents a safe, non-immunogenic, non-viral gene editing solution. This new in vivo gene editing system targets up to 90% of known mutations, covering insertions, deletions, transitions, and transversions. NeuBase’s technology offers the promise of fundamentally addressing disease at its very source, by recruiting the body’s own natural editing machinery to correct the underlying mutations that cause it.
Use of Forward-Looking Statements
Our innovative PATrOL™ platform and Stealth Editing™ technology have the potential to revolutionize the industry. Unfortunately, this potential is surrounded by risks and uncertainties that make predictions more uncertain. Factors like global health conditions, our ability to protect our intellectual property rights, and the availability of capital to advance these product candidates can all affect our actual results and deviate them from what was disclosed in our forward-looking statements. We are working towards creating the best products possible but due to the unpredictable nature of the future, we cannot guarantee results. Nevertheless, we remain committed to our mission and will continue to strive towards developing the best product offerings.